AP2000001977A0 - The process for manufacturing topical opthalmic preparations without systemic effects. - Google Patents
The process for manufacturing topical opthalmic preparations without systemic effects.Info
- Publication number
- AP2000001977A0 AP2000001977A0 APAP/P/2000/001977A AP2000001977A AP2000001977A0 AP 2000001977 A0 AP2000001977 A0 AP 2000001977A0 AP 2000001977 A AP2000001977 A AP 2000001977A AP 2000001977 A0 AP2000001977 A0 AP 2000001977A0
- Authority
- AP
- ARIPO
- Prior art keywords
- topical
- systemic
- preparations
- timolol
- clonidine
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 4
- 230000009885 systemic effect Effects 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 abstract 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 abstract 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
- 229960002896 clonidine Drugs 0.000 abstract 2
- 229960004605 timolol Drugs 0.000 abstract 2
- 206010000087 Abdominal pain upper Diseases 0.000 abstract 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 1
- 229930003347 Atropine Natural products 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
- 229930182566 Gentamicin Natural products 0.000 abstract 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 206010022998 Irritability Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 229930193140 Neomycin Natural products 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 206010041349 Somnolence Diseases 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 206010046555 Urinary retention Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 229960002610 apraclonidine Drugs 0.000 abstract 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- 229960002537 betamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract 1
- 208000006218 bradycardia Diseases 0.000 abstract 1
- 230000036471 bradycardia Effects 0.000 abstract 1
- 229960003679 brimonidine Drugs 0.000 abstract 1
- 229960004484 carbachol Drugs 0.000 abstract 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002612 cardiopulmonary effect Effects 0.000 abstract 1
- 229960003405 ciprofloxacin Drugs 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 206010013781 dry mouth Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 229960003704 framycetin Drugs 0.000 abstract 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 abstract 1
- 229960002518 gentamicin Drugs 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 229960001798 loteprednol Drugs 0.000 abstract 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 230000003547 miosis Effects 0.000 abstract 1
- 239000003604 miotic agent Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 229960004927 neomycin Drugs 0.000 abstract 1
- 229940023490 ophthalmic product Drugs 0.000 abstract 1
- 208000035824 paresthesia Diseases 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN90BO1999 IN185228B (enrdf_load_stackoverflow) | 1999-02-03 | 1999-02-03 | |
| PCT/IN2000/000008 WO2000049990A2 (en) | 1999-02-03 | 2000-02-02 | The process for manufacturing topical ophthalmic preparations without systemic effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000001977A0 true AP2000001977A0 (en) | 2000-12-31 |
Family
ID=11077485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/001977A AP2000001977A0 (en) | 1999-02-03 | 2000-02-02 | The process for manufacturing topical opthalmic preparations without systemic effects. |
Country Status (11)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| AU2005220199B2 (en) * | 2000-07-14 | 2007-03-08 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| HUP0303197A3 (en) * | 2000-07-14 | 2008-03-28 | Allergan Inc | Compositions containing alpha-2 adrenergic agonist components |
| DE10132876A1 (de) * | 2001-07-06 | 2003-01-30 | Medproject Pharma Entwicklungs | Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| NZ552325A (en) | 2004-05-25 | 2010-11-26 | Sansrosa Pharmaceutical Dev Inc | The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders |
| EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| FR2977493B1 (fr) | 2011-07-05 | 2014-02-14 | Galderma Res & Dev | Nouvelle composition anesthesique stable pour la reduction des reactions cutanees |
| BR112015019546A2 (pt) | 2013-02-15 | 2017-07-18 | Allergan Inc | implante de distribuição de drogas prolongado |
| WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| JP2018521000A (ja) | 2015-05-29 | 2018-08-02 | シドネキシス，インク． | Ｄ２ｏで安定化された医薬製剤 |
| GB202110420D0 (en) * | 2021-07-20 | 2021-09-01 | Rosemont Pharmaceuticals Ltd | Liquid pharmaceutical composition of clonidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056684B2 (ja) * | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
| DD294174A5 (de) * | 1990-05-04 | 1991-09-26 | Sigrid Keipert | Ophthalmika mit retardwirkung und ein neues verfahren zu ihrer herstellung |
| FR2678832B1 (fr) * | 1991-07-10 | 1995-03-17 | Europhta Sa Laboratoire | Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation. |
| FR2679773A1 (fr) * | 1991-07-30 | 1993-02-05 | Merck Sharp & Dohme | Preparation ophtalmique contenant un agent osmotique acceptable antimicrobien. |
| DE19614823A1 (de) * | 1996-04-15 | 1997-10-16 | Mann Gerhard Chem Pharm Fab | Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge |
-
1999
- 1999-02-03 IN IN90BO1999 patent/IN185228B/en unknown
-
2000
- 2000-02-02 AP APAP/P/2000/001977A patent/AP2000001977A0/en unknown
- 2000-02-02 WO PCT/IN2000/000008 patent/WO2000049990A2/en not_active Application Discontinuation
- 2000-02-02 EP EP00925571A patent/EP1139970A2/en not_active Withdrawn
- 2000-02-02 IL IL13882400A patent/IL138824A0/xx unknown
- 2000-02-02 CA CA002326690A patent/CA2326690A1/en not_active Abandoned
- 2000-02-02 BR BR0004530-6A patent/BR0004530A/pt not_active Application Discontinuation
- 2000-02-02 EA EA200000918A patent/EA200000918A1/ru unknown
- 2000-02-02 AU AU44291/00A patent/AU4429100A/en not_active Abandoned
- 2000-02-02 ID IDW20002252A patent/ID28121A/id unknown
- 2000-11-01 ZA ZA200006252A patent/ZA200006252B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN185228B (enrdf_load_stackoverflow) | 2000-12-09 |
| EP1139970A2 (en) | 2001-10-10 |
| BR0004530A (pt) | 2001-04-03 |
| AU4429100A (en) | 2000-09-14 |
| WO2000049990A3 (en) | 2001-07-26 |
| CA2326690A1 (en) | 2000-08-31 |
| IL138824A0 (en) | 2001-10-31 |
| ID28121A (id) | 2001-05-03 |
| EA200000918A1 (ru) | 2001-10-22 |
| ZA200006252B (en) | 2001-11-29 |
| WO2000049990A2 (en) | 2000-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2000001977A0 (en) | The process for manufacturing topical opthalmic preparations without systemic effects. | |
| WO2004071469A3 (en) | Methods of administering a dermatological agent to a subject | |
| CA2633594C (en) | Means and methods for the treatment of tumorous diseases | |
| US9216167B2 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| AU2003301747A8 (en) | Pharmaceutical compositions suitable for the treatment of ophthalmic diseases | |
| MXPA05008140A (es) | Una composicion farmaceutica de rapida accion. | |
| BR0313575A (pt) | Método de transporte transdermal de produtos farmacêuticos topicamente administrados, veìculo, composição de veìculo, composição farmacêutica e uso de um ou mais complexos de derivados de fosfato de compostos farmaceuticamente aceitáveis lipofìlicos com outros excipientes | |
| AU2001288460A1 (en) | Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
| PL370536A1 (en) | Compositions for treatment of common cold | |
| WO2006093784A3 (en) | Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents | |
| JP2005528359A5 (enrdf_load_stackoverflow) | ||
| El Maalouf et al. | Could we expect to improve survival in small cell lung cancer? | |
| US6444676B1 (en) | Use of PARP inhibitors in the treatment of glaucoma | |
| WO2001074365A3 (en) | An efficacious dosage regimen of galantamine that reduces side effects | |
| WO2005011618A3 (en) | Methods for the treatment of male and female sexual dysfunction | |
| AU2003290015A1 (en) | Mastitis treatment | |
| WO2001041747A3 (de) | Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs | |
| WO2005076829A3 (en) | Stable loratadine spill resistant formulation | |
| MX2022013391A (es) | Pauta posologica para el tratamiento del cancer. | |
| WO2003047697A3 (en) | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer | |
| US6663850B2 (en) | Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation | |
| WO2004030623A3 (en) | Nitroxide radioprotector formulations and methods of use | |
| WO2000061171A3 (en) | Uses of mammalian ox2 protein and related reagents |